Australia - English - Department of Health (Therapeutic Goods Administration)

camurus pty ltd - buprenorphine, quantity: 160 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

Ireland - English - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - buprenorphine hydrochloride - sublingual tablet - 2 milligram(s) - drugs used in opioid dependence; buprenorphine

Ireland - English - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - buprenorphine hydrochloride - sublingual tablet - 8 milligram(s) - drugs used in opioid dependence; buprenorphine

Ireland - English - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - buprenorphine hydrochloride - sublingual tablet - 0.4 milligram(s) - drugs used in opioid dependence; buprenorphine

Australia - English - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; levulinic acid; oleyl oleate; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - buprenorphine aup patches are indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - requires daily, continuous, long-term treatment,buprenorphine aup patches are not indicated for use in chronic non-cancer pain other than in exception circumstances. buprenorphine aup patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; levulinic acid; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - buprenorphine aup patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,buprenorphine aup patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine aup patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: povidone; levulinic acid; oleyl oleate; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - buprenorphine aup patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,buprenorphine aup patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine aup patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; polyethylene terephthalate; levulinic acid; povidone; ethyl acetate; 2-ethylhexyl acrylate; glycidyl methacrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate; butyl acrylate; acrylic acid; aluminium acetylacetonate; heptane - buprenorphine aup patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,buprenorphine aup patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine aup patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine -